J
Julie Veziant
Researcher at University of Auvergne
Publications - 42
Citations - 915
Julie Veziant is an academic researcher from University of Auvergne. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 9, co-authored 29 publications receiving 583 citations. Previous affiliations of Julie Veziant include Institut national de la recherche agronomique.
Papers
More filters
Journal ArticleDOI
Gut microbiota imbalance and colorectal cancer.
Johan Gagnière,Jennifer Raisch,Julie Veziant,Nicolas Barnich,Richard Bonnet,Emmanuel Buc,Marie-Agnès Bringer,Denis Pezet,Mathilde Bonnet +8 more
TL;DR: The possible links between the bacterial microbiota and colorectal carcinogenesis are discussed, focusing on dysbiosis and the potential pro-carcinogenic properties of bacteria, such as genotoxicity and other virulence factors, inflammation, host defenses modulation, bacterial-derived metabolism, oxidative stress and anti-oxidative defenses modulation.
Journal ArticleDOI
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Romain Villeger,Amélie Lopès,Guillaume Carrier,Guillaume Carrier,Julie Veziant,Elisabeth Billard,Nicolas Barnich,Johan Gagnière,Emilie Vazeille,Mathilde Bonnet +9 more
TL;DR: The new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency are described.
Journal ArticleDOI
Microbial markers in colorectal cancer detection and/or prognosis.
Romain Villeger,Amélie Lopès,Julie Veziant,Johan Gagnière,Nicolas Barnich,Elisabeth Billard,Delphine Boucher,Mathilde Bonnet +7 more
TL;DR: The microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, and the potential use of microbial variation markers for non-invasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas are discussed.
Journal ArticleDOI
Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer.
Amélie Lopès,Elisabeth Billard,Al Hassan Casse,Romain Villeger,Julie Veziant,Gwenaëlle Roche,Guillaume Carrier,Pierre Sauvanet,Arnaud Briat,Franck Pagès,Souad Naimi,Denis Pezet,Nicolas Barnich,Bruno Dumas,Mathilde Bonnet +14 more
TL;DR: The findings suggest that CoPEC could promote a procarcinogenic immune environment through impairment of antitumor T‐cell response, leading to tumoral resistance to immunotherapy, and could be a new biomarker predicting the anti‐PD‐1 response in CRC.
Journal ArticleDOI
Association of colorectal cancer with pathogenic Escherichia coli: Focus on mechanisms using optical imaging
Julie Veziant,Johan Gagnière,E. Jouberton,Virginie Bonnin,Pierre Sauvanet,Denis Pezet,Nicolas Barnich,Elisabeth Miot-Noirault,Mathilde Bonnet +8 more
TL;DR: Data showed that infection with the pathogenic E. coli strain enhanced inflammation and ROS production in tumors before tumor growth, providing tools to better understand host-pathogen interactions at the early stage of disease, such as inflammatory bowel disease and colorectal cancer.